Cargando…
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text rem...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782816/ https://www.ncbi.nlm.nih.gov/pubmed/36372731 http://dx.doi.org/10.1016/j.ebiom.2022.104330 |
_version_ | 1784857428434616320 |
---|---|
author | Liu, Honghu Wang, Yan Huang, Yilan Xiong, Di Shen, Jie Siqueiros, Lisa Bala, Veenu Savage, George M. Guerrero, Mario Corado, Katya Rosen, Marc I. Fletcher, Courtney V. Daar, Eric S. |
author_facet | Liu, Honghu Wang, Yan Huang, Yilan Xiong, Di Shen, Jie Siqueiros, Lisa Bala, Veenu Savage, George M. Guerrero, Mario Corado, Katya Rosen, Marc I. Fletcher, Courtney V. Daar, Eric S. |
author_sort | Liu, Honghu |
collection | PubMed |
description | BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text reminders. METHODS: Participants were recruited from HIV clinics in Los Angeles and were randomised 1:1 to IS or usual care (UC) group. Adherence to ARVs (primary outcome) was measured by IS system (IS group only), plasma ARV concentration, and self-report. IS-measured adherence was clustered by group-based trajectory model and was validated by ARV concentration summarized by integrated pharmacokinetic adherence measure (IPAM) score. HIV RNA viral load (VL) was compared between IS and UC group. FINDINGS: A total of 112 (IS = 54, UC = 58) participants who completed baseline with at least one follow-up data collection were included in analyses. Overall satisfaction rate for the IS system was >90%. The IPAM score was higher (0.018, 95% CI: −0.098–0.134, p = 0.75) and VL decayed faster (−0.020, 95% CI: −0.042–0.002, p = 0.08) in the IS group compared with the UC group. The ingestible sensor system was well tolerated by study participants. INTERPRETATION: The IS system was well accepted by participants and its use was associated with improved adherence and lower HIV RNA VL. The findings provide a potentially effective strategy for improving adherence. FUNDING: This work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/10.13039/100000002National Institutes of Health (NIH). Y. Wang was in part supported by the NIMH/NIH award T32MH080634. E. Daar was in part supported by the National Center for Advancing Translational Sciences through 10.13039/100007185UCLA10.13039/100006975CTSI Grant UL1TR001881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. |
format | Online Article Text |
id | pubmed-9782816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-97828162022-12-24 Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial Liu, Honghu Wang, Yan Huang, Yilan Xiong, Di Shen, Jie Siqueiros, Lisa Bala, Veenu Savage, George M. Guerrero, Mario Corado, Katya Rosen, Marc I. Fletcher, Courtney V. Daar, Eric S. eBioMedicine Articles BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text reminders. METHODS: Participants were recruited from HIV clinics in Los Angeles and were randomised 1:1 to IS or usual care (UC) group. Adherence to ARVs (primary outcome) was measured by IS system (IS group only), plasma ARV concentration, and self-report. IS-measured adherence was clustered by group-based trajectory model and was validated by ARV concentration summarized by integrated pharmacokinetic adherence measure (IPAM) score. HIV RNA viral load (VL) was compared between IS and UC group. FINDINGS: A total of 112 (IS = 54, UC = 58) participants who completed baseline with at least one follow-up data collection were included in analyses. Overall satisfaction rate for the IS system was >90%. The IPAM score was higher (0.018, 95% CI: −0.098–0.134, p = 0.75) and VL decayed faster (−0.020, 95% CI: −0.042–0.002, p = 0.08) in the IS group compared with the UC group. The ingestible sensor system was well tolerated by study participants. INTERPRETATION: The IS system was well accepted by participants and its use was associated with improved adherence and lower HIV RNA VL. The findings provide a potentially effective strategy for improving adherence. FUNDING: This work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/10.13039/100000002National Institutes of Health (NIH). Y. Wang was in part supported by the NIMH/NIH award T32MH080634. E. Daar was in part supported by the National Center for Advancing Translational Sciences through 10.13039/100007185UCLA10.13039/100006975CTSI Grant UL1TR001881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Elsevier 2022-11-10 /pmc/articles/PMC9782816/ /pubmed/36372731 http://dx.doi.org/10.1016/j.ebiom.2022.104330 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Liu, Honghu Wang, Yan Huang, Yilan Xiong, Di Shen, Jie Siqueiros, Lisa Bala, Veenu Savage, George M. Guerrero, Mario Corado, Katya Rosen, Marc I. Fletcher, Courtney V. Daar, Eric S. Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title_full | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title_fullStr | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title_full_unstemmed | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title_short | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial |
title_sort | ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: an open-label, usual care-controlled, randomised trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782816/ https://www.ncbi.nlm.nih.gov/pubmed/36372731 http://dx.doi.org/10.1016/j.ebiom.2022.104330 |
work_keys_str_mv | AT liuhonghu ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT wangyan ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT huangyilan ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT xiongdi ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT shenjie ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT siqueiroslisa ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT balaveenu ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT savagegeorgem ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT guerreromario ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT coradokatya ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT rosenmarci ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT fletchercourtneyv ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial AT daarerics ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial |